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ABSTRACT
The persistence of androgen receptor (AR) signalling in castrate-resistant 
prostate cancer (CRPC) highlights the unmet clinical need for the development of 
more effective AR targeting therapies. A key mechanism of therapy-resistance is 
by selection of AR mutations that convert anti-androgens to agonists enabling the 
retention of androgenic signalling in CRPC. To improve our understanding of these 
receptors in advanced disease we developed a physiologically-relevant model to 
analyse the global functionality of AR mutants in CRPC. Using the bicalutamide-
activated ARW741L/C mutation as proof of concept, we demonstrate that this mutant 
confers an androgenic-like signalling programme and growth promoting phenotype 
in the presence of bicalutamide. Transcriptomic profiling of ARW741L highlighted key 
genes markedly up-regulated by the mutant receptor, including TIPARP, RASD1 
and SGK1. Importantly, SGK1 expression was found to be highly expressed in the 
KUCaP xenograft model and a CRPC patient biopsy sample both of which express 
the bicalutamide-activated receptor mutant. Using an SGK1 inhibitor, ARW741L 
transcriptional and growth promoting activity was reduced indicating that exploiting 
functional distinctions between receptor isoforms in our model may provide new and 
effective therapies for CRPC patients.
INTRODUCTION
Prostate cancer (PC) is the leading cause of male 
cancer deaths in the western world and remains a major 
challenge to treat effectively [1, 2]. At presentation, 
PC growth is androgen-dependent hence the mainstay 
for treatment is hormone-ablation therapy using anti-
androgens and/or androgen-deprivation therapies (ADT) 
[3, 4]. These act to repress the androgen receptor (AR), 
a member of the nuclear hormone receptor family of 
transcription factors that regulates expression of genes 
involved in prostate growth and transformation. By 
directly competing for androgen binding, anti-androgens 
such as bicalutamide, prevent activation of the AR and 
hence cause tumour regression [3, 5]. Unfortunately, the 
cancer invariably re-appears in an androgen-independent 
form, termed castrate-resistant PC (CRPC), that is largely 
fatal. Importantly, the AR signalling axis is active in this 
advanced stage of disease and thus remains a suitable 
therapeutic target [2, 6]. Indeed, the development of 
second generation anti-androgen and ADT therapies, such 
as enzalutamide [7], ARN-509 [8] and abiraterone [9] 
have shown promise in the treatment of CRPC. However, 
response rates of just 50% and the development of 
resistance has limited their success in the clinic [10–12].
Aberrant AR signalling is a hallmark of CRPC and 
is driven by numerous mechanisms including AR gene 
amplification [13], somatic receptor mutation [14, 15], 
expression of AR splice variants [16] and de-regulated co-
factor expression [17, 18] that facilitate receptor activity 
in castrate conditions and contribute to treatment failure. 
Post-translational modification of the AR represents an 
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additional level of receptor regulation with acetylation of 
key residues in the hinge region of the receptor playing 
a pivotal role in contact-independent growth and tumour 
development in vivo [19].
The acquisition of AR mutations during ADT, that 
either facilitate transcriptional activity of the receptor in 
the absence of androgens or switch anti-androgens to AR 
agonists, is a well characterised mechanism of hormone 
escape and has been reported to occur in upwards of 60% 
of CRPC patients [3, 14]. Importantly, the frequency of 
AR mutations in primary disease is low, but is elevated 
in advanced disease through therapy-specific selection of 
aberrantly functioning receptors [14, 15]. For example, 
chronic treatment with the anti-androgens bicalutamide 
and flutamide regularly drives selection of respective 
ARW741L/C and ARH874Y/ART877A mutations that utilise the 
agents as agonists to promote androgenic signalling and 
tumour cell growth [1]. More recently, the identification 
of an ARF876L mutation in patient samples refractory to 
enzalutamide and ARN-509 therapies has indicated that 
this is a phenomenon not limited to first-generation anti-
androgens [20–22].
Modelling the function of CRPC-relevant AR 
mutants in their native context is challenging with 
most studies utilising non-PC cell lines, ectopically-
expressed variant receptors and luciferase reporter-based 
transcriptional assays [15, 23, 24]. Outside of LNCaP 
cell studies, that express the ART877A mutant, there is a 
paucity of information on the functional dynamics and 
global transcriptomics of CRPC-associated AR mutants 
in a physiological setting that is likely to provide key 
biomarkers and additional treatment regimens for anti-
androgen-resistant malignancies. Moreover, a major 
consideration for the development of next-generation AR-
targeted therapies is whether they will be effective against 
pre-existing AR mutants in CRPC hence the development 
of key research tools to facilitate these studies is of high 
priority. To address this, we have developed a novel 
RNAi-rescue approach that utilises stable expression 
of specific AR mutants in LNCaP cells depleted of the 
endogenous receptor to facilitate more robust analyses of 
aberrant receptor signalling. Therefore, it is now possible 
to assess global transcriptional activity and sensitivity of 
CRPC-associated AR mutants to new receptor-targeting 
agents in a more relevant cellular context. Using the 
ARW741L variant as a paradigm, we demonstrate that this 
mutant activates several endogenous AR-target genes, 
including PSA and TMPRSS2, and promotes a hyper-
proliferative phenotype in the presence of bicalutamide; a 
phenomenon that can be reversed by depletion of ARW741L. 
Global transcriptomics identified a sub-set of ARW741L-
driven genes that are markedly up-regulated compared to 
the endogenous receptor, including SGK1, TIPARP and 
RASD1. Importantly, treatment with an SGK inhibitor 
down-regulated bicalutamide-driven receptor activity and 
cell growth, suggesting this could be a novel avenue of 
treatment for bicalutamide-resistant patients. In all, we 
have successfully applied a novel AR replacement strategy 
to physiologically model the ARW741L mutation in disease 
and highlighted key distinctions in receptor activity that 
could be therapeutically-exploited for improved CRPC 
treatment.
RESULTS
Generation of an RNAi-rescue strategy for 
testing AR mutant activity
There is a paucity of physiologically-relevant 
information on the distinct functionality of CRPC-
associated AR mutants and how they drive aggressive 
PC malignancy. Studies to date have primarily utilised 
reporter-based assays incorporating ectopically-expressed 
mutant receptors to assess activity and sensitivity to 
receptor-targeting agents in AR null cell lines [14]. 
Although useful to demonstrate that specific CRPC-
associated receptor mutants are activated by distinct 
ligands and down-regulated by first- and second-generation 
anti-androgens, as demonstrated in Supplementary Figures 
S1A and S1B, the failure to assess global functionality 
of these aberrantly functioning receptors in this context 
is a major problem. Improved models for examining 
CRPC-relevant AR mutations are therefore required. To 
address this, we developed a more physiological read-
out for AR mutant activity using an siRNA-mediated 
receptor replacement strategy in the androgenic 
LNCaP PC cell line. Using the bicalutamide-activated 
ARW741L as a paradigm for this study (Supplementary 
Figure S1), in part due to its relevance in current clinical 
practise, we generated an LNCaP derivative that stably 
expressed FLAG-tagged ARW741L, called LNCaP-ARW741L 
(Figure 1A). We next designed siRNA oligonucleotides 
(termed siART877A) to discriminately deplete endogenous 
ART877A (approximately 90% knockdown) by targeting the 
3′-UTR of the AR transcript that is absent in ectopically-
expressed ARW741L mRNA (see Supplementary Table 
S2 for sequences). These oligonucleotides down-
regulated endogenous AR and PSA levels in LNCaP 
cells (Supplementary Figure S2A) and attenuated DHT-
induced ART877A recruitment to cis-regulatory elements of 
the PSA gene (Supplementary Figure S2B). Importantly, 
siART877A failed to reduce levels of ectopically-expressed 
FLAG-AR in PC3 cells, while an oligonucleotide targeted 
to the coding region of the AR (siAR) down-regulated 
expression of this protein (Supplementary Figure S3A 
and S3B). In the context of the LNCaP-ARW741L cell line, 
as expected, siART877A reduced endogenous AR levels, 
but did not affect expression of the ARW741L variant 
(Figure 1A). Importantly, an siRNA targeted specifically 
to the linker region between the FLAG-tag and translation 
start site of the ARW741L transcript markedly depleted the 
ectopically-expressed protein, but failed to impact on 
endogenous ART877A.
Oncotarget3www.impactjournals.com/oncotarget
To assess if expression of the bicalutamide-activated 
mutant impacts on the behaviour of the LNCaP derivative 
cell line, we firstly investigated the expression of known 
AR target genes PSA, FKBP5 (Figure 1B), KLK2 and 
TMPRSS2 (Supplementary Figure S4) in the presence 
and absence of 1 nM DHT, 10 nM bicalutamide (pro-
proliferative dose; see Supplementary Figure S5) or vehicle 
control and compared to parental LNCaP cells. As expected, 
AR-target gene expression was up-regulated by DHT, but 
not bicalutamide, in LNCaP cells and this effect could 
be negated by depletion of endogenous ART877A (Figure 
1B and Supplementary Figure S4A). In contrast, both 
DHT and bicalutamide enhanced transcription in LNCaP-
ARW741L cells, and depletion of ART877A further increased 
bicalutamide-activated FKBP5 and TMPRSS2 expression 
(Figure 1C and Supplementary Figure S4B), suggesting a 
potential inhibitory role of ART877A when both receptors are 
co-expressed. The effect of bicalutamide on these genes 
was specific to the ARW741L variant as knockdown using the 
siARW741L oligonucleotide abolished anti-androgen-driven 
transcription, but still enabled endogenous ART877A to drive 
gene expression in the presence of DHT (Figure 1C and 
Supplementary Figure S4B).
Bicalutamide-activated ARW741L is recruited to 
AR-target genes and enhances cell proliferation
We next investigated recruitment of ARW741L to 
endogenous cis-regulatory elements of the AR-target genes 
PSA and TMPRSS2 in response to 1 nM DHT and 10 nM 
bicalutamide using a FLAG antibody. In cells expressing 
both AR variants (siSCR), DHT and bicalutamide activated 
a subtle increase in recruitment of FLAG-ARW741L to these 
loci (Figure 2A). Consistent with gene expression data 
(Figure 1), depletion of endogenous ART877A markedly 
elevated bicalutamide-activated ARW741L recruitment to the 
PSA enhancer and TMPRSS2 promoter and this effect was 
diminished upon ectopic ARW741L knockdown. Moreover, 
ARW741L is also recruited to the promoter of the KLK2 gene 
in response to bicalutamide and this can be attenuated with 
Figure 1: Stably-integrated ARW741L in LNCaP cells up-regulates endogenous PSA and FKBP5 in the presence of 
bicalutamide. A. Western analysis of parental and ARW741L-expressing LNCaP cells depleted of either endogenous (siART877A) or ectopic 
(siARW741L) receptors using AR, FLAG (to detect FLAG-tagged ARW741L) and α-tubulin antibodies. Scrambled siRNA (siScr) was used 
as a transfection control. Quantitative PCR analysis of PSA and FKBP5 expression in parental LNCaP cells B. and the LNCaP-ARW741L 
derivative C. depleted of either endogenous or ectopic receptors treated with 1 nM DHT or 10 nM bicalutamide for 24 hours. Data 
represents the mean of three independent experiments ± standard error.
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ectopic receptor knockdown (Supplementary Figure S6). 
Importantly, using a phospho-serine 5 RNA polymerase II 
antibody as a marker of transcriptional initiation, we found that 
DHT- and bicalutamide-activated ARW741L can facilitate the 
assembly of the transcriptional machinery to drive expression 
of endogenous PSA and TMPRSS2 genes (Figure 2B).
We next examined the effect of ARW741L on 
proliferation of the LNCaP-ARW741L derivative cell line 
in response to 1 nM DHT and 10 nM bicalutamide, 
and compared to parental LNCaP cells. As shown in 
Figure 2C, growth of LNCaP cells was increased by 
DHT and this effect was reduced by siART877A, but not 
siARW741L. In contrast, growth of LNCaP-ARW741L was 
markedly increased in the presence of both DHT and 
bicalutamide and only depletion of ARW741L abolished 
bicalutamide-driven growth of these cells. To demonstrate 
that these findings were not an artefact of this specific 
clonal population of ARW741L-expressing cells, we tested 
an additional selected derivative (Clone 2) against the 
original (Clone 1; utilised in all previous experiments) and 
a control transduced cell line (LNCaP-LacZ) that does not 
overexpress ARW741L. Importantly, both Clone 1 and Clone 
2 showed comparable growth stimulation in response to 
DHT and bicalutamide and was distinct from LNCaP-LacZ 
that only responded to DHT (Supplementary Figure S7).
ARW741L is inactivated by enzalutamide
Enzalutamide has shown great promise in the clinic 
[25], but the fact that not all patients respond to the drug 
may indicate the existence of a pre-determinant, such as 
an AR mutant, that compromises enzalutamide efficacy 
[20, 21]. Given that enzalutamide in many cases is given 
as a second-line therapy post-bicalutamide treatment, it 
is therefore important to establish if the ARW741L mutant 
is sensitive to enzalutamide in our more robust CRPC 
model system. To this end, we firstly assessed the effect 
of 10 μM enzalutamide on bicalutamide-activated 
ARW741L transcriptional activity in LNCaP-ARW741L cells. 
As expected, bicalutamide up-regulated PSA and KLK2 
Figure 2: ARW741L is recruited to cis-regulatory elements of AR-target genes and drives a pro-proliferative phenotype 
in response to bicalutamide. A. LNCaP-ARW741L cells depleted of either endogenous or ectopic AR were treated with 1 nM DHT or 
10 nM bicalutamide for 4 hours prior to chromatin immunoprecipitation (ChIP) analysis using a FLAG antibody to immunoprecipitate 
FLAG-ARW741L. Receptor recruitment to the PSA enhancer (PSA Enh) and TMPRSS2 promoter was assessed by quantitative PCR. 
B. LNCaP-ARW741L cells depleted of endogenous receptor and treated with 1 nM DHT or 10 nM bicalutamide for 4 hours were subject to 
ChIP analysis using a phospho-Serine 5 RNA polymerase II antibody (pSer5 Pol II) and enrichment at PSA and TMPRSS2 genes measured 
by quantitative PCR. C. LNCaP cells or the LNCaP-ARW741L derivative depleted of endogenous or ectopic AR were grown in the presence 
of 1 nM DHT or 10 nM bicalutamide for 96 hours prior to SRB staining. Percentage growth is relative to vehicle control for each siRNA. 
Data is the mean of triplicate experiments ± standard error.
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gene expression, and importantly, this was reduced to 
basal levels upon administration of enzalutamide (Figure 
3A). Furthermore, ChIP analysis using a FLAG antibody 
demonstrated that enzalutamide markedly diminished 
bicalutamide-activated ARW741L recruitment to cis-
regulatory elements of the PSA, TMPRSS2 and KLK2 
genes (Figure 3B and Supplementary Figure S8).
In proliferation assays, we showed that enzalutamide 
reduced growth of both parental and ARW741L-expressing 
LNCaP cells (Figure 3C and Supplementary Figure S9). 
Importantly, enzalutamide attenuated bicalutamide-driven 
proliferation of LNCaP-ARW741L cells (Figure 3D) indicating 
that this second-generation anti-androgen is likely to be 
effective in CRPC patients harbouring the ARW741L mutation.
ARW741L drives an androgenic signalling 
programme similar to ART877A
We next tested the utility of this model to provide 
much needed information on the global transcriptional 
targets of the CRPC-relevant ARW741L mutant. Using 
LNCaP-ARW741L cells depleted of endogenous ART877A, the 
expression profile of ARW741L in response to bicalutamide 
was compared to vehicle treated controls and a total of 
869 genes were identified as being upregulated >1.5 fold 
(Figure 4A and 4B; siART877A). This threshold was chosen 
as it fell within fold change cut-offs that have been used in 
previous publications investigating AR signalling profiles 
[26–28]. As a control, LNCaP-LacZ cells were treated 
with 10 nM bicalutamide and the resultant transcriptome 
was compared to the gene list identified in LNCaP-
ARW741L cells. Importantly, no genes were identified in 
the LNCaP-LacZ control line that exhibited >1.5 fold 
up-regulation in the presence of bicalutamide, suggesting 
that the identified set of bicalutamide-induced genes in 
the LNCaP-ARW741L cells were specific to the ectopically-
expressed receptor (Figure 4A and 4B). To refine the list of 
core bicalutamide-induced genes further, we incorporated 
an additional control in which the expression profile of 
bicalutamide-treated LNCaP-ARW741L cells depleted of 
ARW741L was examined relative to siART877A vehicle and 
bicalutamide-stimulated experimental arms (Figure 4A 
Figure 3: Bicalutamide-driven ARW741L activity and LNCaP-ARW741L cell growth is attenuated by enzalutamide.  
A. LNCaP-ARW741L cells depleted of endogenous AR were treated with 10 nM bicalutamide +/− 10 μM enzalutamide for 24 hours prior to 
quantitative analysis of AR target gene expression. B. LNCaP-ARW741L cells transfected with siScr or siART877A were treated for 4 hours with 
either 1 nM DHT or bicalutamide +/− 10 μM enzalutamide prior to ChIP and quantitative PCR analysis using primers specific to AR-target 
genes. C. LNCaP cells or the LNCaP-ARW741L derivative depleted of endogenous or ectopic AR were grown in the presence of 1 nM DHT, 
10 nM bicalutamide or 10 μM enzalutamide for 96 hours prior to SRB staining. Percentage growth is relative to vehicle control for each 
siRNA. Data is the mean of triplicate experiments ± standard error. D. As for (C) except LNCaP-ARW741L cells depleted of endogenous AR 
were treated with 10 nM bicalutamide +/− increasing doses of enzalutamide to a maximum of 30 μM prior to SRB staining.
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and 4B; siARW741L). Genes that exhibited > 2 fold increase 
in expression following bicalutamide treatment in 
ARW741L-depleted cells were deemed to be bicalutamide-
independent. We identified 38 genes matching to the 869 
core data set that were subsequently eliminated (Figure 
4A and 4B); resulting in a refined gene set of 831 genes 
whose expression were considered to be specifically 
driven by bicalutamide-activated ARW741L. The full list of 
bicalutamide-induced genes are listed in Supplementary 
Table S4 and include characterised AR-target genes such 
as PSA, KLK2, TMPRSS2, NKX3.1, KCNN2 and SPOCK1
We next compared the bicalutamide-driven 
transcriptome of LNCaP-ARW741L with the DHT-
stimulated LNCaP-LacZ cell line derivative. In response 
to 1 and 10 nM DHT, microarray analysis revealed 
113 and 491 up-regulated genes, respectively, relative 
to vehicle control (Figure 4C; Supplementary Tables 
S5 and S6). Comparison of both gene lists found 86 
common genes (76% and 17% of 1 nM and 10 nM DHT 
up-regulated genes, respectively), highlighting a core 
set of androgen-regulated target genes that are activated 
in response to both 1 nM and 10 nM DHT (Figure 4C). 
As expected, a greater number of genes were activated 
in response to 10 nM DHT than 1 nM DHT, including 
FKBP5 (Supplementary Figure S10).
Direct comparison of the bicalutamide-induced 
LNCaP-ARW741L expression profile to the core set of 
androgen-regulated genes in LNCaP-LacZ, found that 
41 of the 86 genes (48%) were common to both lists 
(Figure 4D). For example, PSA (KLK3) and KLK2, 
which were found to be the most DHT-stimulated in 
LNCaP-LacZ cells were also elevated in response to 
bicalutamide in LNCaP-ARW741L cells and is consistent 
with LNCaP-ARW741L gene expression data (Figure 1C). 
We next compared the bicalutamide-activated ARW741L 
transcriptome with two published androgenic gene 
signatures acquired from LNCaP cells [27, 29]. Of the 
respective 21 and 79 androgen-induced genes identified 
in the two studies, 15/21 (71%) and 52/79 (66%) matched 
directly to genes identified in the bicalutamide-activated 
Figure 4: Bicalutamide activates an androgenic gene signature programme in LNCaP-ARW741L. LNCaP-ARW741L cells 
depleted of either endogenous or ectopic AR were treated with 10 nM bicalutamide for 24 hours prior to micro-array analysis. Resultant 
transcriptome was compared to control LNCaP-LacZ cells treated with 10 nM bicalutamide. Genes with a fold increase of >1.5 were 
considered to be ligand regulated and included in the analysis. Genes with a bicalutamide-induced fold increase of >2.0 in the ARW741L-
depleted experimental arm were eliminated from the core list of bicalutamide-induced genes. Data is presented as a heat map A. and Venn 
diagram B, C. LNCaP-LacZ control cells were treated with either 1 or 10 nM DHT for 24 hours prior to micro-array analysis to identify a 
core of DHT-regulated genes between each condition. D. Overlap between bicalutamide-induced ARW741L transcriptome and the identified 
set of 86 core DHT-up-regulated genes in the LNCaP-LacZ cells.
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LNCaP-ARW741L data-set (Supplementary Figure S11; see 
Supplementary Table S7), indicating robust commonality 
between the bicalutamide-induced ARW741L and DHT-
stimulated ART877A transcriptional programmes.
Exploiting ARW741L-driven SGK1 expression to 
inactivate CRPC cell growth
We next focused our attention on identifying 
ARW741L-driven genes that were significantly elevated 
in response to bicalutamide and distinct from our 
DHT-stimulated LNCaP-LacZ transcriptome to define 
biomarkers of this specific CRPC-associated AR 
mutation and potentially highlight avenues for therapeutic 
exploitation. Of the top 20 bicalutamide up-regulated 
genes in LNCaP-ARW741L cells (Figure 5A), several were 
well known AR target genes, including FKBP5 and 
NDRG1,  and are elevated in response to 10 nM DHT 
treatment in our LNCaP-LacZ control line (Supplementary 
Table S6). Importantly, array data indicated that TIPARP 
(TCDD-inducible poly(ADP-ribose) polymerase), RASD1 
(Ras dexamethasone-induced 1) and SGK1 (serum- and 
glucocorticoid-regulated kinase 1) were exclusively and 
markedly up-regulated by bicalutamide in the LNCaP-
ARW741L cell line compared to the DHT-stimulated control 
LNCaP-LacZ derivative (data not shown). Robust 
bicalutamide-mediated up-regulation of TIPARP (57-fold), 
RASD1 (93-fold) and SGK1 (109.5-fold) was validated 
by QPCR, and demonstrated to be exclusively mediated 
by ARW741L as depletion of this mutant by siARW741L 
completely abrogated gene expression (Figure 5B). In 
contrast, treatment of LNCaP-LacZ cells with a dose-
range of DHT (Figure 5B and Supplementary Figure S12) 
only modestly increased SGK1 (5-fold) and RASD1 
(2-fold) expression and failed to elevate TIPARP transcript 
levels while, as expected, PSA was greatly up-regulated 
(Supplementary Figure S13). Moreover, analysis of an 
additional LNCaP derivative that ectopically expresses 
wild-type AR (LNCaP-wtAR) to levels comparable to 
that of ARW741L (data not shown), demonstrated modest 
enhancement of SGK1, TIPARP and RASD1 transcription 
in response to DHT stimulation with respective 4.5-, 
8.6- and 5.9-fold induction, indicating that the robust up-
regulation of the three genes in LNCaP-ARW741L cells is 
not due to the phenomenon of elevated cellular AR levels 
(Supplementary Figure S14).
To investigate further the discriminate enhancement 
of TIPARP, RASD1 and SGK1 by ARW741L, we profiled 
expression of these genes in the KUCaP xenograft CRPC 
model. This xenograft was derived from a liver metastasis 
present in a bicalutamide-resistant CRPC patient and 
exclusively expresses the ARW741C mutation [30]. As shown 
in Figure 5C, expression of TIPARP, RASD1 and SGK1 
were markedly elevated in KUCaP cells compared to the 
LNCaP line confirming that key distinctions exist between 
transcriptomes of ARW741L and ART877A that could be 
important in the pathobiology of disease in CRPC patients 
harbouring the bicalutamide-resistant mutation.
To address if the distinct gene-set of ARW741L could 
be exploited to provide key targets for CRPC therapy, we 
focussed on the potent up-regulation of SGK1 expression 
by this mutant receptor. Given that a previous study 
indicated that inactivation of SGK1 using the selective 
inhibitor GSK650394 reduces SGK1 expression and 
LNCaP cell growth [31], we hypothesised that the 
LNCaP-ARW741L derivative may be sensitive to this agent 
as they demonstrate markedly elevated SGK1 expression 
compared to our LNCaP control cells (Figure 5B). To 
this end, we assessed ARW741L-driven expression of SGK1 
in the presence and absence of 10 μM GSK650395; a 
dose demonstrated to down-regulate SGK1 transcript 
levels in LNCaP cells [31]. As shown in Figure 6A, 
treatment of LNCaP-ARW741L cells with GSK650395 
reduced expression of SGK1 by approximately 50% 
indicating that activity of the bicalutamide-activated 
receptor is potentiated by SGK1 and attenuation of 
the associated kinase activity down-regulates ARW741L-
mediated transcription. Importantly, SGK1 inhibition 
reduced LNCaP-ARW741L proliferation by approximately 
70% (Figure 6B) indicating SGK1 is a key down-stream 
effector of ARW741L-driven cell growth.
Finally, we conducted a systematic in silico 
analysis of a comprehensive PC cohort containing 150 
primary tumour samples [32] and identified one patient 
biopsy expressing the ARW741C mutation. Consistent with 
our findings from the LNCaP-ARW741L derivative and 
KUCaP xenograft, SGK1 gene expression was found to 
be significantly up-regulated in this sample compared to 
all other samples suggesting that this may be a bona fide 
biomarker for aberrant ARW741L function (Figure 6C and 
Supplementary Figure S15) and manipulating activity of 
this enzyme may provide an additional means of treatment 
for CRPC patients resistant to bicalutamide.
DISCUSSION
The selection of AR mutations during androgen-
depravation therapy is a well-defined mechanism of 
therapy resistance that, to date, has been reported to occur 
in upwards of 60% advanced CRPC patients [14, 15]. 
Although unclear, this figure may increase further due 
to two key developments: (i) the utility of more sensitive 
approaches for detecting mutations in both diagnostic and 
basic research [32], and (ii) ease of access to disseminated 
disease through the study of circulating tumour cells that 
offers a non-invasive means for AR sequencing in CRPC 
[33, 34]. Importantly, the presence of mutant AR in 
CRPC poses particular clinical challenges as many of the 
identified mutations promote promiscuous receptor activity 
that enable androgenic signalling by non-conventional 
ligands, including bicalutamide, flutamide [14], and more 
recently, enzalutamide/ARN-509 [10, 21]; hence limiting 
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available treatment options in advanced disease. From a 
biological perspective, our understanding of the global 
functioning of these aberrant receptors is remarkably 
limited. Outside of studies in the PC cell lines LNCaP, 
that harbour the ART877A mutation, and CWR22RV1, that 
express ARH874Y and also numerous alternatively spliced 
AR isoforms, there is a reliance upon transient expression 
of mutant receptors in non-androgenic cell lines to study, 
in most cases, the transcriptional dynamics of these 
proteins [23, 24]. Although useful, these experiments 
offer little or no insight into global transcriptomics of 
AR mutants and lack physiological context. Given the 
prevalence of AR mutations in advanced CRPC, defining 
their activity in more robust and disease-relevant models 
is imperative to help improve our understanding of these 
receptors and to potentially exploit their distinct activities 
for the development of new PC treatments.
To this end, we developed a novel RNAi-rescue 
system to enable the study of AR mutants in the 
physiological background of LNCaP cells that have 
been depleted of the endogenous receptor. Using the 
bicalutamide-activated ARW741L as a proof of concept 
mutation, that is also clinically-relevant, we generated 
an LNCaP cell line derivative that stably-expressed 
this mutant receptor (LNCaP-ARW741L) and developed 
key siRNAs to deplete either endogenous or ectopic 
ART877A and ARW741L, respectively. Using this model, we 
demonstrated that in the presence of bicalutamide, ARW741L 
associates with cis-regulatory elements of several AR target 
genes, including PSA and TMPRSS2, and facilitates their 
expression. Significantly, these effects were attenuated 
upon depletion of the ectopic receptor indicating that the 
bicalutamide-driven functionality of ARW741L previously 
characterised in AR null cell line studies (Supplementary 
Figure S1 and [35]) has been phenocopied in LNCaP cells 
with promotion of chromatin-binding and endogenous 
target gene expression by the anti-androgen akin to the 
DHT-activated endogenous ART877A isoform. Interestingly, 
data from both chromatin immunoprecipitation and 
candidate gene expression analysis (PSA, TMPRSS2, 
KLK2) experiments demonstrated an inhibitory effect 
of ART877A on bicalutamide-activated ARW741L when both 
receptor isoforms were expressed (siScr control; Figures 1 
and 2). We hypothesise that dimerization between the two 
distinct proteins may occur in the presence of bicalutamide 
and impact on their activity; homodimers of ARW741L 
Figure 5: ARW741L markedly up-regulates genes distinct from endogenous ART877A. A. Top 20 bicalutamide-induced 
genes identified in siART877A-transfected LNCaP-ARW741L cells. B. LNCaP cells and LNCaP-ARW741L depleted of endogenous or ectopic 
receptors, were treated with either DHT (1 and 10 nM) or 10 nM bicalutamide for 24 hours prior to quantitative analysis of SGK1, 
RASD1 and TIPARP expression. C. Expression analysis of the same genes was compared between LNCaP cells and the ARW741C-
expressing KUCaP xenograft model.
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will be transcriptionally potent, while ART877A-ARW741L 
heterodimers are likely to be functionally compromised. 
By depleting endogenous ART877A from LNCaP cells, the 
equilibrium is pushed toward the generation of active 
ARW741L dimers to promote more robust AR-target gene 
binding and transcription.
To further support the utility of this RNAi-rescue 
system to model distinct CRPC-relevant AR mutations, 
we demonstrated that the ARW741L mutant promoted 
growth of the LNCaP derivative line in the presence of 
bicalutamide. The pro-proliferative effect of bicalutamide 
was solely driven by the activity of ARW741L confirming 
that the ectopic receptor replaces the activity of ART877A 
and illustrates the ability for this model to recapitulate 
conditions of a bicalutamide-resistant CRPC disease state.
From these promising indications, we next tested 
the impact of the second-generation anti-androgen 
enzalutamide on mutant activity and growth of the 
LNCaP-ARW741L derivative. This is a particularly important 
experiment when one considers that new AR-targeting 
compounds will be applied to advanced, ADT-resistant 
CRPC that are likely to harbour pre-existing AR mutations 
[3]; hence defining efficacy of agents toward CRPC-
relevant receptor mutations in a physiological model 
system is critical for optimal pre-clinical drug testing. In 
both the presence and absence of bicalutamide, ARW741L-
chromatin binding, endogenous target gene expression 
and LNCaP-ARW741L growth was down-regulated by 
enzalutamide indicating that this mutation is sensitive 
to the second-generation anti-androgen. From this study, 
it is therefore possible to predict that patients refractory 
to bicalutamide through the selection of specific AR 
mutations are likely to demonstrate a clinical response 
to enzalutamide. However, given that up to 50% of 
patients do not respond to enzalutamide [7, 25], it is likely 
that other pre-determinants in advanced disease may 
compromise AR-targeting agent efficacy; the selection 
of other distinct mutations during first-line ADT could 
represent one such mechanism of new treatment failure. 
Importantly, our novel rescue system would enable 
the robust modelling of other CRPC-relevant receptor 
mutants that could facilitate patient stratification towards 
those predicted to receive benefit from sequential anti-AR 
targeted therapy and those that would not.
In keeping with the utility of this model as an 
important pre-clinical tool to identify distinctions in 
the functionality of disease-associated AR mutations, 
we hypothesised that global transcriptomic profiling 
Figure 6: SGK1 inhibition reduces ARW741L activity and attenuates LNCaP-ARW741L proliferation. A. LNCaP-ARW741L cells 
depleted of ART877A were treated with 10 μM SGK inhibitor GSK650395 for 24 hours prior to quantitative analysis of SGK1 expression. 
B. As above, but cells were treated with GSK650395 for 96 hours in the presence and absence of 10 nM bicalutamide prior to proliferation 
analysis. C. In silico SGK1, TIPARP and RASD1 expression profiling in 150 primary prostate cancer specimens (28); ARW741C-expressing 
patient sample is indicated in green.
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of ARW741L would provide key gene targets that could 
be exploited for novel CRPC treatment strategies. 
Examination of the bicalutamide-activated ARW741L target 
gene-set against a control transduced LNCaP derivative 
(LNCaP-LacZ) identified a series of bicalutamide-
induced genes; many of which were known AR-target 
genes including PSA, KLK2 and TMPRSS2. Furthermore, 
although the number of bicalutamide-activated genes 
were in excess of those controlled by DHT in our control 
cells and those reported in Hieronymous et al., [29] and 
Nelson et al., [27] there was considerable overlap in the 
bicalutamide- and androgen-activated transcriptomes 
supporting the concept that ARW741L maintains a common 
androgenic expression programme. Importantly, a 
number of robustly up-regulated bicalutamide-dependent 
genes were identified by micro-array in LNCaP-ARW741L 
cells that were not greatly enhanced by DHT in the 
LNCaP-LacZ line, including TIPARP, RASD1 and 
SGK1. Depletion of ectopic receptor in LNCaP-ARW741L 
cells attenuated this bicalutamide-driven response 
indicating that these genes are potentially discriminate 
targets of ARW741L. This dramatic and selective activity 
of the ARW741L mutant is intriguing and may be a 
consequence of subtle allosteric re-organisation of the 
receptor that permits hyper-activation of the receptor at 
distinct genomic loci. By repositioning the C-terminal 
activation function-2 (AF-2) domain of the receptor, 
the leucine residue may enable more robust interaction 
with selective co-regulators to drive acetylation 
and methylation of the AR to enhance inherent 
transcriptional activity [19, 36].
In contrast to our data, however, SGK1 has been 
identified to be robustly up-regulated by endogenous 
ART877A in LNCaP cells and the gene product found to 
positively reinforce androgenic signalling [31, 37]. 
The discrepancy between our data and these findings 
is intriguing and may reflect key differences in 
experimental design and performance, as although we 
did detect a 3-fold and 4.5-fold enhancement of SGK1 
expression in response to 10 nM DHT by quantitative 
PCR in the respective LNCaP-LacZ and LNCaP-wtAR 
cell derivatives, it was significantly less than previous 
reported.
Importantly, the same study provided evidence that 
inactivation of SGK1 with the selective small molecule 
inhibitor GSK650395 was able to attenuate LNCaP cell 
proliferation in the presence of DHT [31]. Therefore, 
given that LNCaP-ARW741L cells demonstrated marked up-
regulation of SGK1 expression in response to bicalutamide, 
we speculated that they may also be sensitive to SGK1 
inhibition. Consistent with the reported phenomenon in 
parental LNCaP cells [31], we found that ARW741L-driven 
SGK1 expression was down-regulated in response to 
GSK650395 treatment, suggesting that ectopic receptor 
function is dependent upon SGK1-mediated kinase 
activity. Furthermore, proliferation of both LNCaP and 
LNCaP-ARW741L cells was significantly down-regulated 
upon SGK1 inhibition; with similar IC50 values for both 
cell lines in response to GSK650395 (Supplementary 
Figure S16). Importantly, in the LNCaP-ARW741L cells, 
this anti-proliferative effect was maintained in the 
presence of a pro-proliferative dose of bicalutamide. We 
have therefore identified a strongly up-regulated ARW741L 
target gene that may offer an avenue for therapeutic 
exploitation in bicalutamide-refractory CRPC. Although 
these observations are based on our rescue model system, 
evidence from the patient-derived KUCaP xenograft and 
a single patient biopsy sample, that both harbour the 
bicalutamide-activated ARW741C mutation [30, 32], is in 
agreement with our findings of elevated SGK1 expression 
and suggests utility of our RNAi-rescue approach to define 
global functionality of the ARW741L mutation.
In all, we have established a novel LNCaP cell 
line-based strategy to model CRPC-relevant mutations to 
provide important information on receptor dynamics and 
global gene signalling in response to distinct activating 
ligands.
MATERIALS AND METHODS
Luciferase reporter, quantitative PCR and 
western analyses
Luciferase assays were performed in HEK293T 
cells grown in steroid-depleted media as described in [38] 
utilising the p(ARE)3 reporter and pFLAG-AR, -ARW741L 
and –ARH874Y. Quantitative PCR was used to assess 
expression of endogenous AR-and ARW741L-target genes 
(see Supplementary Table S1 for primer sequences) using 
cDNA generated from Trizol-mediated RNA extractions 
as described in [39]. Western blotting was performed as 
described in [40] using antibodies listed in Supplementary 
Table S3.
Cell proliferation assays
Sulforhodamine B (SRB) assays were performed 
according to [41]. Briefly, 5 × 103 LNCaP or LNCaP-
ARW741L cells per well of a 96-well plate grown in 
steroid-depleted conditions were transfected with siScr, 
siART877A or siARW741L for 96 hours as described above 
before fixing in trichloroacetic acid for 1 hour at 4°C. 
Cells were washed and subsequently stained with 0.4% 
SRB dissolved in 1% acetic acid. Plates were air dried at 
room temperature, after which bound SRB was dissolved 
in 10 mM Tris-HCl, pH 10.8. Absorbance was measured 
at 570 nm using a 96-well plate reader (BioRad). For drug 
treatments, 10 nM bicalutamide, 1 nM DHT, or increasing 
doses of enzalutamide, were administered for 96 hours 
prior to SRB assay.
For additional Methods please refer to accom-
panying Supplementary Information.
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